Retina:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for India Healthcare Professionals only

      Ozurdex+logo+RGB_LT
      Ozurdex+logo+RGB_LT
      ozurdex+lozenge+2
      oz+right+side+fix-gigapixel-art-scale-2_00x


      OZURDEX® injection support resources:
       

      Stay or Switch?

      Primary author Dr Catharina Busch, University Hospital Leipzig, discusses continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory DMO.

       

      OZURDEX+Injection+Guide_800x600px_DIGITAL_2024_v8.0_LT_Page_1+small

      Step-by-step injection guide

      Download this digital guide to familiarise yourself with the steps to follow prior to, during and post-injection of OZURDEX®.

       

      Injection technique animation

      Watch this short video to see an animated version of the OZURDEX® injection procedure.

       

      Patient counselling video

      Hear top tips from Mr Al-Bermani, Consultant Ophthalmologist at the University Hospital of Wales, on how to put patients at ease before, during and after the OZURDEX® injection procedure. 

       

      DMO, diabetic macular oedema; RVO, retinal vein occlusion.

      1. OZURDEX®. Summary of Product Characteristics; 2. Garcia-Layana A, et al. Ophthalmologica. 2018;240:61–72.; 3. Wang K, et al. Biol Pharm Bull. 2008;31:1541–6; 4. Rezar-Dreindl S, et al. Acta Ophthalmol. 2017;95:e119–27; 5. Edelman JL, et al. Exp Eye Res. 2005;80:249–58; 6. Tamura H, et al. Invest Ophthalmolo Vis Sci. 2005;46(4):1440–4; 7. Nehme A and Edelman J. Invest Ophthalmol Vis Sci. 2008;49:2030–8.

      OZURDEX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 


      Date of preparation: January 2025 | UK-OZU-250040